Pro-angiogenic approach for skeletal muscle regeneration

Floriano, Juliana Ferreira; Costa, Sarah Maria Barneze; Vega, Sofía; Barbosa, Angélica Mércia Pascon; Oliveira, Rafael Guilen de; Floriano, Emerson Aparecido Ferreira; Graeff, Carlos Frederico de Oliveira; Abbade, Joélcio Francisco; Herculano, Rondinelli Donizete; Sobrevía, Luis; Rudge, Marilza Vieira Cunha

doi:10.1016/j.bbagen.2021.130059

Cited by 12 publications

(11 citation statements)

References 336 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF administration and VEGF receptor modulation are two treatments that aid in pro-angiogenic induction. Pro-angiogenic therapies have been shown to increase the number of MuSCs and stimulate myogenesis 19 , 60 . Lack of dystrophin in DMD may result in altered morphology and properties of the ECs, potentially altering blood vessel function 20 .…”

Section: Evidence For Angiogenic Alterations In Animal Models Of Duch...mentioning

confidence: 99%

Vascular therapy for Duchenne muscular dystrophy (DMD)

Thapa¹,

Elhadidy²,

Asakura³

2023

Fac Rev

View full text Add to dashboard Cite

Duchenne muscular dystrophy (DMD) is a progressive disease characterized by the wasting of the muscles that eventually lead to difficulty moving and, ultimately, premature death from heart and respiratory complications. DMD deficiency is caused by mutations in the gene encoding dystrophin , which prevents skeletal muscle, cardiac muscle, and other cells from producing the functional protein. Located on the cytoplasmic face of the plasma membrane of muscle fibers, dystrophin serves as a component of the dystrophin glycoprotein complex (DGC), mechanically reinforces the sarcolemma, and stabilizes the DGC, preventing it from contraction-mediated muscle degradation. In DMD muscle, dystrophin deficiency leads to progressive fibrosis, myofiber damage, chronic inflammation, and dysfunction of the mitochondria and muscle stem cells. Currently, DMD is incurable, and treatment involves the administration of glucocorticoids in order to delay disease progression. In the presence of developmental delay, proximal weakness, and elevated serum creatine kinase levels, a definitive diagnosis can usually be made after an extensive review of the patient’s history and physical examination, as well as confirmation through muscle biopsy or genetic testing. Current standards of care include the use of corticosteroids to prolong ambulation and delay the onset of secondary complications, including respiratory muscle and cardiac functions. However, different studies have been carried out to show the relationship between vascular density and impaired angiogenesis in the pathogenesis of DMD. Several recent studies on DMD management are vascular targeted and focused on ischemia as a culprit for the pathogenesis of DMD. This review critically discusses approaches—such as modulation of nitric oxide (NO) or vascular endothelial growth factor (VEGF)-related pathways—to attenuate the dystrophic phenotype and enhance angiogenesis.

show abstract

Section: Evidence For Angiogenic Alterations In Animal Models Of Duch...mentioning

confidence: 99%

Vascular therapy for Duchenne muscular dystrophy (DMD)

Thapa¹,

Elhadidy²,

Asakura³

2023

Fac Rev

View full text Add to dashboard Cite

show abstract

“…Vascularization is a critical aspect of skeletal muscle homeostasis in adapting to exercise, as well as in regeneration [17,[93][94][95]. ERRs are one of the first orphan receptors to be explored in understanding how skeletal muscle directly regulates its own vasculature in a paracrine fashion.…”

Section: Paracrine Angiogenesis and Muscle Vascularizationmentioning

confidence: 99%

Estrogen-related Receptor Signaling in Skeletal Muscle Fitness

Sopariwala¹,

Nguyen²,

Narkar³

2023

Int J Sports Med

View full text Add to dashboard Cite

Skeletal muscle is a highly plastic tissue which can alter its metabolic and contractile features, as well as regenerative potential in response to exercise and other conditions. Multiple signaling factors including metabolites, kinases, receptors and transcriptional factors have been studied in the regulation of skeletal muscle plasticity. Recently, estrogen-related receptors (ERRs) have emerged as a critical transcriptional hub in control of skeletal muscle homeostasis. ERRα and ERRγ - the two highly expressed ERR sub-types in the muscle respond to various extracellular cues such as exercise, hypoxia, fasting and dietary factors, in turn regulating gene expression in the skeletal muscle. On the other hand, conditions such as diabetes and muscular dystrophy suppress expression of ERRs in the skeletal muscle, likely contributing to disease progression. We highlight key functions of ERRs in the skeletal muscle including the regulation of fiber type, mitochondrial metabolism, vascularization and regeneration. We also describe how ERRs are regulated in the skeletal muscle, and their interaction with important muscle regulators (e.g. AMPK and PGCs). Finally, we identify critical gaps in our understanding of ERR signaling in the skeletal muscle, and suggest future areas of investigation to advance ERRs as potential targets for function promoting therapeutics in muscle diseases.

show abstract

“…The biological actions of circulating angiogenic growth factors are enhanced due to the involvement of exosomes, which display a high capacity of delivering miRs, proteins, and other particles targeting cells with high angiogenic activity [ 103 ].…”

Section: Exosomes In Skeletal Muscle Repair and Regenerationmentioning

confidence: 99%

The Therapeutic Potential of Exosomes in Soft Tissue Repair and Regeneration

Wan

Hussain

Behfar

et al. 2022

IJMS

View full text Add to dashboard Cite

Soft tissue defects are common following trauma and tumor extirpation. These injuries can result in poor functional recovery and lead to a diminished quality of life. The healing of skin and muscle is a complex process that, at present, leads to incomplete recovery and scarring. Regenerative medicine may offer the opportunity to improve the healing process and functional outcomes. Barriers to regenerative strategies have included cost, regulatory hurdles, and the need for cell-based therapies. In recent years, exosomes, or extracellular vesicles, have gained tremendous attention in the field of soft tissue repair and regeneration. These nanosized extracellular particles (30–140 nm) can break the cellular boundaries, as well as facilitate intracellular signal delivery in various regenerative physiologic and pathologic processes. Existing studies have established the potential of exosomes in regenerating tendons, skeletal muscles, and peripheral nerves through different mechanisms, including promoting myogenesis, increasing tenocyte differentiation and enhancing neurite outgrowth, and the proliferation of Schwann cells. These exosomes can be stored for immediate use in the operating room, and can be produced cost efficiently. In this article, we critically review the current advances of exosomes in soft tissue (tendons, skeletal muscles, and peripheral nerves) healing. Additionally, new directions for clinical applications in the future will be discussed.

show abstract

Pro-angiogenic approach for skeletal muscle regeneration

Cited by 12 publications

References 336 publications

Vascular therapy for Duchenne muscular dystrophy (DMD)

Vascular therapy for Duchenne muscular dystrophy (DMD)

Estrogen-related Receptor Signaling in Skeletal Muscle Fitness

The Therapeutic Potential of Exosomes in Soft Tissue Repair and Regeneration

Contact Info

Product

Resources

About